Eosinophil activation in systemic sclerosis

Gustafsson, Rolf; Hällgren, Roger; Fredens, Kjeld; Nettelbladt, O

doi:10.1002/art.1780340406

Cited by 52 publications

(31 citation statements)

References 51 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is not known whether or not eosinophils are continuously mobilised from the bone marrow during disease development in SSc but remain in the peripheral circulation for a longer period of time, or if eosinophil mobilisation increases as disease duration progresses. During early disease, however, eosinophils appear to home to peripheral tissues to a greater extent than in later disease stages, as described by Gustafsson et al [16].…”

Section: Discussionmentioning

confidence: 76%

“…The cutoff was therefore set to 2 years, since this cut-off is commonly used in clinical trials of treatments regimes for the disease. Also, the initial study of eosinophils in SSc by Gustafsson et al [16] suggests a role for eosinophils early during disease pathogenesis. The data suggest a disease duration dependent dynamic evolution of the expression of the surface marker CD81…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

CD81 and CD48 show different expression on blood eosinophils in systemic sclerosis: new markers for disease and pulmonary inflammation?

Wuttge

Andreasson

Tufvesson

et al. 2015

Scandinavian Journal of Rheumatology

View full text Add to dashboard Cite

Objective: In systemic sclerosis (SSc) related interstitial lung disease, elevated eosinophil counts in bronchoalveolar lavage are associated with worse outcome. We hypothesize that eosinophils are activated in the peripheral circulation, thereby increasing their recruitment to affected tissues and contributing to inflammation and fibrosis. The aim of this study was to characterize the blood eosinophils in SSc patients. Methods:Expressions of surface markers CD11b, CD44, CD48, CD54, CD69, CD81 and HLA-DR on CD16 low CD9 high expressing eosinophils were measured by flow cytometry in whole blood from SSc patients (n = 32) and controls (n = 11).Results: Expression of CD54, CD69 and HLA-DR were undetectable in all groups. CD44and CD11b expression levels were similar between groups. CD81 expression was lower in patients compared to controls independent of disease duration (p = 0.001). CD48 expression was increased in patients with a short disease duration (< 2 years) compared to both controls (p = 0.042) and patients with longer disease duration (p = 0.027). In patients with short disease duration, increased CD48 expression was associated with alveolar inflammation as measured by an increased concentration of alveolar nitric oxide (r = 0.76, p = 0.003). Conclusion:Blood eosinophils change phenotype during disease evolution in SSc, and CD48 expression may be used as a biomarker for pulmonary inflammation.

show abstract

Section: Discussionmentioning

confidence: 76%

Section: Discussionmentioning

confidence: 99%

CD81 and CD48 show different expression on blood eosinophils in systemic sclerosis: new markers for disease and pulmonary inflammation?

Wuttge

Andreasson

Tufvesson

et al. 2015

Scandinavian Journal of Rheumatology

View full text Add to dashboard Cite

show abstract

“…Eosinophils are believed to be important for tissue remodelling in asthma and may also play a role in interstitial pulmonary disease [10]. With regard to SSc, increased serum levels of eosinophil cationic protein indicating eosinophil activation has been associated with decreased lung function [24]. However, the role of eosinophils in the pathogenesis of fibrosis in SSc remains to be elucidated.…”

Section: Discussionmentioning

confidence: 99%

BALF-derived fibroblasts differ from biopsy-derived fibroblasts in systemic sclerosis

Scheja¹,

Larsen²,

Todorova³

et al. 2007

European Respiratory Journal

View full text Add to dashboard Cite

Growth of fibroblasts from bronchoalveolar lavage fluid (BALF) in patients with systemic sclerosis (SSc) has previously been described. The purpose of the present study was to characterise fibroblasts from BALF and bronchial biopsies from SSc patients with alveolitis and from controls, to analyse fibroblast proliferation, migration, stress fibres and proteoglycan production.BALF and bronchial biopsies were collected from 10 patients with SSc and alveolitis and from 15 controls.Outgrowth of fibroblasts was observed from the BALF of four patients, particularly in those with a markedly increased percentage of eosinophils in BALF, but not in any member of the control group. Increased levels of granulocyte-macrophage colony-stimulating factor, correlating with the percentage of eosinophils in BALF, were found in patients when compared with controls. Fibroblasts from BALF showed an elongated, mobile phenotype and increased proteoglycan production compared to the corresponding biopsy fibroblasts.In conclusion, outgrowth of fibroblasts with an altered phenotype is reported from bronchoalveolar lavage fluid in systemic sclerosis patients with alveolitis and an increased percentage of eosinophils in the bronchoalveolar lavage fluid. These findings indicate a possible role for eosinophil-fibroblast interaction in pulmonary fibrosis in systemic sclerosis.

show abstract

“…Monocyte activation is also reported, as documented by increased production in the peripheral blood of superoxide anion (24), , IL-1, and TGF␤ (26). Other cells that are found to be activated in SSc include eosinophils (27), mast cells (18), and T cells (28)(29)(30)(31). Disease-associated autoantibodies such as antitopoisomerase I (anti-topo I) antibodies (1), and hypergammaglobulinemia in general, have been observed in patients with SSc, and their production requires both T and B cells (32).…”

Section: Introductionmentioning

confidence: 99%